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with acute heart failure (AHF) being one of the most
ommon and costly reasons for hospitalizations in the U.S.,
stablishing the clinical utility of B-type natriuretic peptide
BNP) and aminoterminal pro–B-type natriuretic peptide
NT-proBNP) testing has been an important advance in
his area. With thousands of papers published, a decade of
linical experience, and perhaps the only heart failure
iomarker to have its own guidelines endorsement (1), the
ar has been set very high for newer biomarkers to demon-
trate their potential uses in the management of patients
ith AHF.
See page 2062
The importance of atrial natriuretic peptide and ad-
enomedullin as compensatory neurohumoral pathways has
een extensively described in the literature over the past few
ecades. Animal models have identified both measurements
s potent hormones with vasodilatory and natriuretic prop-
rties (2,3). In patients with heart failure, both play impor-
ant roles in maintaining cardiorenal homeostasis. Both
ave been isolated in cardiovascular tissues, and their
etectable increase in plasma levels has long been described
n the setting of heart failure (4,5). In fact, both hormones
ave even been developed as vasodilator drugs for therapeu-
ic use (6). Although measurements have been limited to
esearch-based assays and were hindered by their relatively
hort half-lives and instability, plasma levels of both hor-
ones have been associated with adverse long-term out-
omes (7,8).
In this issue of the Journal, the BACH (Biomarkers in
cute Heart Failure) trial investigators (9) tested the hy-
othesis that measuring 2 stable mid-region fragments of
ro-hormones for atrial natriuretic peptide (MR-proANP)
nd adrenomedullin (MR-proADM) can provide incre-
ental diagnostic value in the detection of AHF and
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.P
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t the emergency department. The BACH trial followed a
inning formula of contemporary biomarker studies by
ompleting a large multicenter study design led by world-
lass investigators, performing sophisticated statistical anal-
ses, and achieving the pre-specified end points to claim
ignificance. In the era of evidence-based medicine, such a
ell-conducted study provides important insights and is
reatly appreciated. At the same time, results of the BACH
tudy may illustrate emerging challenges facing the transla-
ion of new research findings into clinical practice in the era
f broad adoption of BNP/NT-proBNP testing. The issue
n contention is whether demonstration of more appropriate
iagnosis of AHF (by adding MR-proANP in subsets) and
etter prediction of mortality (by adding MR-proADM)
an adequately translate into better patient management and
linical outcomes.
ddition of MR-proANP to diagnose AHF. The ability to
mprove the diagnostic certainty for detecting AHF has
een the primary indication for BNP/NT-proBNP testing.
t is, therefore, no big surprise that in the BACH trial, there
as impressively tight concordance between measurements
f MR-proANP and measurements made by commercially
vailable BNP or NT-proBNP assays. As prior studies have
uestioned the utility of measuring atrial natriuretic peptide
ecause of its instability and wide variability, this “noninfe-
iority” finding in itself is an important illustration that new
ssay technologies can refine the measurement of a specific
eptide to meet a specific purpose. In other words, the quest
o distinguish differences among various types of natriuretic
eptide tests has only revealed more similarities than dif-
erences. As different fragments of natriuretic peptides are
eing targeted for assay development, a new issue has
merged that is completely independent of whether MR-
roANP can provide equivalent diagnostic accuracy. The
anges of measurements are different between various natri-
retic peptides (and to a lesser degree among multiple
ommercially available assays measuring the same peptide).
urrently, different values are already being reported for
atients cared for at different institutions or locations of care
here various assays (BNP or NT-proBNP) are being used.
roviding yet another type of natriuretic peptide test would
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Biomarker Evidence Into Clinical Practice May 11, 2010:2077–9imply add to the confusion. Hence, in terms of clinical
pplications, harmonization of these test results may be
ecessary to avoid unintentional errors in interpreting the
esults.
The ability to provide incremental diagnostic certainty
ith a multimarker approach is an attractive concept. The
otential for MR-proANP to provide additional insights
as been suggested by its ability to predict long-term risk
ncremental to that of NT-proBNP (10,11) but equivalent
o that of BNP (12) in patients with chronic heart failure.
lthough the prognostic value of MR-proANP was not
eported in this paper, the investigators provided elaborate
nalysis to illustrate the potential incremental diagnostic
nformation with the addition of MR-proANP to BNP and
T-proBNP. While many impressive p values were pre-
ented, these analyses made an important assumption that
linicians were rigid in interpreting BNP or NT-proBNP
alues with pre-defined cutoff values without taking into
ccount potential confounders that may adjust their inter-
retations. Therefore, whether lowering the perceived BNP
utoff to a level optimal for obese patients may provide the
ame diagnostic accuracy as adding MR-proANP to BNP
eeds to be examined. Similarly, whether addition of
T-proBNP to BNP in the “gray zone” can yield similar
ndings as adding MR-proANP to BNP remains to be
xplored. Interestingly, the diagnostic accuracy of BNP
esting in the BACH trial was lower than that previously
eported in the BNP (Breathing-Not-Properly) trial at the
ame cutoff value of 100 pg/ml with the same assay (74% vs.
3%, respectively) (13). This appears to be due to slightly
ower specificity of the test performance in the BACH study
opulation. Although the precise reasons for such difference
ere not elaborated, this lower accuracy may also favor the
ddition of MR-proANP to improve decision statistics.
herefore, in reviewing the data from the BACH trial,
emonstration of direct improvement in clinical outcomes
y enhancing diagnostic accuracy with the addition of
R-proANP, although promising, remains somewhat
acking.
ddition of MR-proADM to predict adverse outcomes
n AHF. The BACH investigators (9) reported the incre-
ental prognostic value for MR-proADM in the same
opulation for both short-term (30-day) and long-term
90-day) outcomes. It is interesting to note that the stron-
est signal for MR-proADM lies in its ability to predict
ortality (both all cause and cardiovascular related), and not
n other end points such as rehospitalization or revisits (in
hich the number of events are much higher). The strength
f this prediction was highest at short-term follow-up, when
he number of events was relatively low (only 35 deaths,
ith 23 cardiovascular related, at up to 30 days) and
ppeared to be confined to patients in the highest quartile of
R-proADM. Furthermore, the incremental prognostic
nformation for MR-proADM within patients with AHF
as shown only for all-cause mortality and not for othervents. In fact, BNP appeared to provide a stronger predic-ion for rehospitalization and revisit than NT-proBNP or
R-proADM, even though all of their areas under the
eceiver-operating characteristic curves were all in the 0.6 to
.7 range at best. Since various noncardiac morbidities such
s sepsis, renal insufficiency, and cancer have been associated
ith heightened adrenomedullin expression as one of many
ounterregulatory mechanisms (14), it is conceivable that
art of the prognostic value of MR-proADM can even be
ndependent of the AHF setting.
The BACH investigators (9) emphasized the potential
or better prognostic markers to identify patients who
hould warrant more immediate therapeutic interventions.
owever, while sicker patients can be identified by high
R-proADM levels, characterizing why they were more
ikely to die may be more insightful than simply pointing
ut that they have a greater likelihood of dying. No doubt
hat better characterization of patients using biomarkers
ay allow better differentiation of phenotypes, although
ometimes the implications of prognostic markers may
ndicate patients who may be less likely (rather than more
ikely) to respond to specific therapy. For example, a recent
ost-hoc analysis suggested that rosuvastatin may be poten-
ially beneficial in lower rather than higher levels of NT-
roBNP in patients with ischemic cardiomyopathy (15).
ence, the potential for clinicians to alter the natural
istory of patients with elevated MR-proADM remained
ighly speculative, particularly if MR-proADM levels have
o direct relationship with subsequent cardiovascular mor-
idity in the setting of AHF.
In summary, this landmark BACH trial has delivered all
he answers to the intended objectives with spectacular
uccess. Despite these promising findings, the results still
ast some doubt as to whether adding these measurements
o existing BNP or NT-proBNP testing can substantially
nfluence current clinical decision making or change the
anagement of patients with AHF. That is because de-
cribing a biomarker’s clinical significance is only one of
any determinants of its potential clinical utility, albeit an
mportant one. As more and more biomarkers emerge on
he horizon, exploring how a specific biomarker can link to
enefits from specific therapeutic intervention will be des-
erately needed to translate evidence into clinical practice.
hat is particularly relevant to conditions such as AHF,
hich has not witnessed any substantial changes in thera-
eutic approaches for the past decades.
eprint requests and correspondence: Dr. W. H. Wilson Tang,
leveland Clinic, 9500 Euclid Avenue, Desk J3-4, Cleveland,
hio 44195. E-mail: tangw@ccf.org.
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